Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft.
Vinci L, Flotho C, Noellke P, Lebrecht D, Masetti R, de Haas V, De Moerloose B, Dworzak M, Hasle H, Güngör T, Starý J, Turkiewicz D, Ussowicz M, de Heredia CD, Buechner J, Jahnukainen K, Kallay K, Bodova I, Smith OP, Zecca M, Bresters D, Lang P, Masmas TN, Meisel R, Pichler H, Erlacher M, Göhring G, Locatelli F, Strahm B, Niemeyer CM, Yoshimi A. Vinci L, et al. Among authors: de haas v. Bone Marrow Transplant. 2023 May;58(5):607-609. doi: 10.1038/s41409-023-01942-4. Epub 2023 Feb 23. Bone Marrow Transplant. 2023. PMID: 36823455 Free PMC article. No abstract available.
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, Halkes CJM, Fijnheer R, Havelange V, van Sluis GL, Legdeur MC, Deeren D, Gadisseur A, Sinnige HAM, Breems DA, Jaspers A, Legrand O, Terpstra WE, Boersma RS, Mazure D, Triffet A, Tick LW, Beel K, Maertens JA, Beverloo HB, Bakkus M, Homburg CHE, de Haas V, van der Velden VHJ, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Rijneveld AW, et al. Among authors: de weerdt o, de haas v. Blood Adv. 2022 Feb 22;6(4):1115-1125. doi: 10.1182/bloodadvances.2021005624. Blood Adv. 2022. PMID: 34883506 Free PMC article. Clinical Trial.
Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair.
Mahmud H, Ter Elst A, Scherpen FJG, Boer TM, Kampen KR, de Haas V, Guryev V, Peppelenbosch MM, Kornblau SM, de Bont ESJM. Mahmud H, et al. Among authors: de haas v, de bont esjm. Oncotarget. 2019 Jul 23;10(45):4679-4690. doi: 10.18632/oncotarget.27086. eCollection 2019 Jul 23. Oncotarget. 2019. PMID: 31384395 Free PMC article.
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, Veerman AJ, van Kessel AG, Hoogerbrugge PM, Kuiper RP, van Dongen JJ. Waanders E, et al. Among authors: de haas v. Leukemia. 2011 Feb;25(2):254-8. doi: 10.1038/leu.2010.275. Epub 2010 Nov 19. Leukemia. 2011. PMID: 21102428
Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.
Hollink IH, Feng Q, Danen-van Oorschot AA, Arentsen-Peters ST, Verboon LJ, Zhang P, de Haas V, Reinhardt D, Creutzig U, Trka J, Pieters R, van den Heuvel-Eibrink MM, Wang J, Zwaan CM. Hollink IH, et al. Among authors: de haas v. Leukemia. 2012 Feb;26(2):371-3. doi: 10.1038/leu.2011.210. Epub 2011 Aug 12. Leukemia. 2012. PMID: 21836609 No abstract available.
132 results